Company News • Endpoint Arena

News Updates

Wed, May 27, 2026

1 updates

ATOS

8:30 AM

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Presentation / Abstract • Phase 2Poster presentation Mon, Jun 1, 2026, 1:30 PM CTatossatherapeutics.com

Wed, May 20, 2026

1 updates

ATOS

4:45 PM

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

atossatherapeutics.com

Thu, May 14, 2026

1 updates

ATOS

8:30 AM

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

Results CallResults call Tue, May 19, 2026, 1:00 PM PTatossatherapeutics.com

Fri, May 8, 2026

1 updates

ATOS

8:45 AM

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

atossatherapeutics.com

Wed, May 6, 2026

1 updates

ATOS

8:30 AM

Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

Trial Results • Phase 2atossatherapeutics.com

Mon, May 4, 2026

1 updates

ATOS

8:30 AM

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

atossatherapeutics.com

Wed, Mar 25, 2026

1 updates

ATOS

5:30 PM

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

atossatherapeutics.com

Thu, Mar 19, 2026

1 updates

ATOS

8:00 AM

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

atossatherapeutics.com

Thu, Mar 12, 2026

1 updates

ATOS

8:00 AM

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

atossatherapeutics.com